BRAF mutation as a prognostic factor in colorectal cancer
Author Information
Author(s): Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y
Primary Institution: Aichi Cancer Center Hospital
Hypothesis
This study investigated the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advanced and recurrent colorectal cancer patients.
Conclusion
The presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent colorectal cancer.
Supporting Evidence
- BRAF mutated tumors were more likely to develop on the right side of the colon.
- The median overall survival for BRAF mutation-positive patients was significantly worse than for patients with wild-type KRAS and BRAF.
- BRAF mutation was associated with poor overall survival after adjustment for significant features.
Takeaway
If a patient has a BRAF mutation, they might not live as long as others with colorectal cancer who don't have this mutation.
Methodology
Patients with advanced and recurrent CRC treated with systemic chemotherapy were analyzed for KRAS/BRAF genotypes by cycleave PCR.
Potential Biases
Potential treatment bias due to the retrospective nature of the study.
Limitations
The study is retrospective and may have treatment bias due to the specific chemotherapy regimens used.
Participant Demographics
The study included 229 Japanese patients with advanced and recurrent colorectal cancer.
Statistical Information
P-Value
P<0.001 for BRAF mutation and overall survival.
Confidence Interval
95% CI 2.08–8.67 for BRAF mutation and overall survival.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website